Source:http://linkedlifedata.com/resource/pubmed/id/19919377
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
2009-12-16
|
| pubmed:abstractText |
Stakeholders in Europe remain interested in assessments of country-specific value of self-monitoring of blood glucose (SMBG) for patients with type 2 diabetes treated with oral anti-diabetes drugs (OADs). This study used the IMS-CORE Diabetes Model to project the long-term (40-year) cost-effectiveness of SMBG at once, twice, or three times per day (vs. no SMBG) for this population from national reimbursement system perspectives in France, Germany, Italy, and Spain.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
1473-4877
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
26
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
163-75
|
| pubmed:meshHeading |
pubmed-meshheading:19919377-Administration, Oral,
pubmed-meshheading:19919377-Blood Glucose Self-Monitoring,
pubmed-meshheading:19919377-Cost-Benefit Analysis,
pubmed-meshheading:19919377-Diabetes Mellitus, Type 2,
pubmed-meshheading:19919377-France,
pubmed-meshheading:19919377-Germany,
pubmed-meshheading:19919377-Humans,
pubmed-meshheading:19919377-Hypoglycemic Agents,
pubmed-meshheading:19919377-Italy,
pubmed-meshheading:19919377-Quality-Adjusted Life Years,
pubmed-meshheading:19919377-Spain
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain.
|
| pubmed:affiliation |
IMS Health, Inc. Falls Church, VA 22046, USA. stunis@us.imshealth.com
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|